In a major new finding almost a decade in the making, researchers say they've found a key that may unlock many of the ...

Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no ...

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose ...

In a major new finding almost a decade in the making, researchers at Harvard Medical School say they've found a key that may ...